Bolus versus Continuous Intravenous Delivery of Doxorubicin in Soft-Tissue Sarcomas: Post Hoc Analysis of a Prospective Randomized Trial (SARC021/TH CR-406).

Lee D Cranmer,Yao Lu,Rachel S Heise,Karla V Ballman,Elizabeth T Loggers,Seth M Pollack,Michael J Wagner,Denise K Reinke,Patrick Schöffski,William D Tap

Clinical cancer research : an official journal of the American Association for Cancer Research（2023）

引用 1|浏览13

暂无评分

摘要

CIV was not associated with superior outcomes over BOL within DOX dosing limits of SARC021. Cardiac AEs were associated with increasing cumulative DOX dose. While not randomized with respect to DOX delivery mode, the results indicate that continued investigation of AE mitigation strategies is warranted.

查看译文

关键词

doxorubicin,soft-tissue soft-tissue sarcomas<i>post,continuous intravenous delivery

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要